Tectonic Therapeutic, Inc.(TECX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TECX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Tectonic Therapeutic, Inc. (TECX), a Healthcare sector company. TECX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Tectonic Therapeutic, Inc. reports net income of $-22.3M, free cash flow of $-21.5M. Top institutional holders of TECX by reported 13-F value include FMR, TCG Crossover Management, abrdn plc, based on the most recent SEC filings. TECX trades on the Nasdaq exchange and files with the SEC under CIK 1681087. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TECX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tectonic Therapeutic, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-22.3M
Free Cash Flow
Q2 2026
$-21.5M
ROIC
Q2 2026
-43.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-27.9% YoYOperating Income
-44.9% YoYEPS (Diluted)
+40.7% YoYTotal Assets
+70.7% YoYTotal Debt
Op. Cash Flow
-1.7% YoYFree Cash Flow
-1.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-74.2M -27.9% | $-58.0M -35.4% | $-42.8M +59.6% | $-105.9M +11.1% | $-119.1M +0.5% | $-119.7M |
| Operating Income | $-84.0M -44.9% | $-58.0M -29.9% | $-44.6M +57.7% | $-105.4M +11.3% | $-118.8M +1.2% | $-120.2M |
| EPS (Diluted) | $-4.05 +40.7% | $-6.83 -547.4% | $-1.05 -1295.5% | $-0.08 +13.0% | $-0.09 | — |
| Total Assets | $261.0M +70.7% | $152.9M +288.1% | $39.4M -62.1% | $103.9M -49.0% | $203.8M -24.8% | $271.2M |
| Total Debt | — | — | — | $15.0M +0.0% | $15.0M | — |
| Operating Cash Flow | $-60.1M -1.7% | $-59.1M -45.2% | $-40.7M +58.2% | $-97.2M +0.8% | $-98.0M +0.8% | $-98.8M |
| Free Cash Flow | $-60.3M -1.8% | $-59.2M -44.6% | $-41.0M +58.0% | $-97.5M +3.0% | $-100.5M -0.5% | $-100.0M |
Get alerted when TECX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Tectonic Therapeutic, Inc. including:
Top Institutional Holders of TECX
FMR LLC
$97.3M2,830,378 shTCG Crossover Management, LLC
$41.4M1,204,891 shabrdn plc
$39.3M1,141,824 shBlackRock, Inc.
$29.7M862,592 shFirst Light Asset Management, LLC
$27.5M800,726 shBAKER BROS. ADVISORS LP
$20.9M607,788 sh5AM Venture Management, LLC
$20.9M606,660 shBRAIDWELL LP
$20.5M596,900 shVANGUARD CAPITAL MANAGEMENT LLC
$16.8M488,805 shVestal Point Capital, LP
$14.6M425,000 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $97.3M | 2,830,378 |
| TCG Crossover Management, LLC | $41.4M | 1,204,891 |
| abrdn plc | $39.3M | 1,141,824 |
| BlackRock, Inc. | $29.7M | 862,592 |
| First Light Asset Management, LLC | $27.5M | 800,726 |
| BAKER BROS. ADVISORS LP | $20.9M | 607,788 |
| 5AM Venture Management, LLC | $20.9M | 606,660 |
| BRAIDWELL LP | $20.5M | 596,900 |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.8M | 488,805 |
| Vestal Point Capital, LP | $14.6M | 425,000 |
More Healthcare Companies
View all Healthcare →Put TECX on your watchlist
Track score changes the day Tectonic Therapeutic, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TECX a good stock to buy?
13F Pro's AI-powered analysis of Tectonic Therapeutic, Inc. (TECX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TECX are available on the TECX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TECX is classified as a small company.
Which hedge funds own TECX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TECX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tectonic Therapeutic, Inc.'s investment landscape.